Diasome Pharmaceuticals
Diasome Pharmaceuticals designs and develops insulin-based therapies for Type 1 and Type 2 diabetes.
Founded
2004Diasome Pharmaceuticals designs and develops insulin-based therapies for Type 1 and Type 2 diabetes.
Founded in 2004 and based in Conshohocken, Pennsylvania, Diasome Pharmaceuticals is a clinical-stage therapeutics company focused on designing and developing advanced insulin-based therapies for Type 1 and Type 2 diabetes. The company's product lineup includes Oral HVD-I, a targeted oral insulin available in pill or gel cap form, HDV-I, an injectable short-acting insulin, and HDV-B, an injectable basal long-acting insulin. Diasome aims to improve glucose balance and lipid regulation in patients, addressing the core challenges of diabetes management.
Diasome Pharmaceuticals has garnered attention for its innovative approach to diabetes treatment, attracting notable investors and industry experts. The company's advancements have positioned it as a significant player in the diabetes therapeutics market. By focusing on the dual role of hepatocytes in glucose and lipid regulation, Diasome's therapies aim to mitigate the risks of hyperglycemia and hypoglycemia, thereby enhancing the quality of life for diabetes patients.
Companies similar to Diasome Pharmaceuticals include Oramed Pharmaceuticals, Htbt, Sensulin and Glycostasis.
Diasome Pharmaceuticals was founded in 2004.
Diasome Pharmaceuticals' headquarters is located in Cleveland, OH, US.
Diasome Pharmaceuticals' most recent funding round was for $9M (USD) in June 2023.
As of Jun 30, 2023, Diasome Pharmaceuticals has disclosed funding of $92M (USD). Undisclosed round amounts are excluded.
Diasome Pharmaceuticals has 5 employees as of Feb 5, 2024.
Glycostasis
